Vivo Cura Health
Calgary, Alberta, T2E2P5, Canada
NCT Number: NCT05283889
Currently, nearly 1 million total knee arthroplasties (TKA) are performed yearly in the United States. Three million are projected to be performed in 2040. Between 15-30% of all patients who undergo TKA have continued pain, reduced quality of life and functional impairments that cannot be attributed to hardware failure/loosening or infection. Treatment options for persistent post TKA pain (failed TKA) are limited. There is a need for minimally invasive, and effective pain and disability modulating interventions for patients with failed TKA. Genicular radiofrequency ablation (GRFA) has been described, refined, and validated as an effective minimally invasive intervention to control refractory knee pain secondary to knee osteoarthritis (OA) as evidenced by three favorable meta-analyses published in 2021 alone.3-5 GRFA is a minimally invasive percutaneous procedure that utilizes thermal energy to coagulate nerves from the knee. Though sometimes used in practice, there is limited research describing and evaluating GRFA for patients with failed TKA. This will be the first trial to evaluate the safety and efficacy of GRFA in patients with failed TKA using a robust study design and up-to-date, evidence-based selection criteria and technique.
This study is active but is not currently recruiting participants.
Notify Me50 year and older
All sexes
Interventional
Not applicable
Calgary, Alberta, T2E2P5, Canada
The general objective of this study is to determine the safety and efficacy of GRFA in patients with failed TKA. The central hypothesis is that GRFA is safe and more efficacious in improving pain and function than sham GRFA. A triple blinded randomized sham-controlled trial design will be used. Patients with failed TKA will be recruited and randomized into either a thermal or sham GRFA group. Patient selection criteria and GRFA procedural technique will incorporate refinements based on expanded understanding from recent research. Outcomes will be assessed prior to and at 3, 6 and 12 months post-GRFA. The primary outcome measures will be between group difference in the change in pain (NRS) between pre- and 6 months post. Secondary outcomes will include safety and changes in function (WOMAC; sit-stand test; strength; range of motion & balance), participants' impression of change, perceived need for revision arthroplasty, analgesic use, and quality-of-life. Crossover will be offered to participants in the sham group at 6 months post-treatment. Data will be analyzed using descriptive, linear mixed-effects model and Kaplan-Meier Survival Curve statistics. The proposed research is innovative and important as it uses a robust study design to evaluate the safety and efficacy of an emerging RFA intervention in a prevalent suffering patient population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Time frame: 6 months
Numerical pain rating scale (0 - 10) with higher scores indicating a worse outcome
Time frame: 6 months
Numerical Pain rating scale (NPRS) 6 month minus NPRS pre-intervention, with increased negative scores indicating a better outcome
Time frame: 3 and 12-months post-intervention
Numerical pain rating scale (0 - 10) with higher scores indicating worse outcomes
Time frame: 3, 6 and 12-months post-intervention
Measure of pain (0 - 20), stiffness (0 - 8) and physical function (0 - 68) with higher scores indicating wore pain, stiffness and functional limitations
Time frame: 3, 6 and 12-months post-intervention
Patient reported global impression of change (1 = Very Much Improved to 7 = Very Much Worse)
Time frame: 1-week, 3, 6 and 12-months post-intervention
Presence of self-reported complications
Time frame: 6 months
Proportion of participants that experience ≥ 50% pain relief
Time frame: 6 months
Proportion of participants that experience MCID knee pain relief
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
"If revision surgery of your knee replacement was available to you, how interested would you be in having it at this time?" Y or N
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
Quantitative Analgesic Questionnaire
Time frame: Baseline (Prior to), 3, 6 and 12-months post-intervention
EQ-5D-5L
University of Calgary
Other
The Safety and Efficacy of Genicular Radiofrequency Ablation for Patients With Persistent Knee Pain Following Total Knee Arthroplasty - A Triple Blinded Randomized Sham-Controlled Trial
Acronym: GRATKA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05349682
Arthritis, Joint Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT05787821
Arthritis, Arthritis, Rheumatoid
Parker, Colorado, United States
View Trial DetailsNCT03466476
Arthritis, Arthroplasty, Replacement, Knee
Miami, Florida, United States
View Trial DetailsNCT02440672
Arthritis, Joint Diseases
Phoenix, Arizona, United States
View Trial Details